Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation

Journal of Medical Virology

Volumn 78, Issue 3, 2006, Pages 394-399

  Von Müller, Lutz ^a   Schliep, Christian ^a   Storck, Martin ^b   Hampl, Walter ^a   Schmid, Thomas ^a   Abendroth, Dietmar ^a   Mertens, Thomas ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Clinical Center Karlsruhe   (Germany)

Author keywords

Cytomegalovirus; Graft rejection; Kidney transplantation

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VIRUS PROTEIN;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CADAVER; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FEVER; GRAFT REJECTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMONIA; SERODIAGNOSIS; SYMPTOMATOLOGY;

ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FEVER; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; LENGTH OF STAY; LEUKOPENIA; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PNEUMONIA; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; VIRAL MATRIX PROTEINS;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 33644652423     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20552     Document Type: Article

References (23)

1. Benz C, Holz G, Michel D, Awerkiew S, Dries V, Stippel D, Goeser T, Busch DH. 2003. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: Case report of a pancreatico-renal transplant recipient. Transplantation 75:724-727.
2. Brennan DC. 2001. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 12:848-855.
3. Brennan DC, Garlock KA, Lippmann BA, Buller RS, Gaudreault-Keener M, Lowell JA, Miller SB, Shenoy S, Howard TK, Storch GA. 1997. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 8:118-125.
4. Cantarovich D, Karam G, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Le NL, Soulillou JP. 1998. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 54:1351-1356.
5. Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M. 2001. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 71:764-767.
6. Fishman JA, Rubin RH. 1998. Infection in organ-transplant recipients. N Engl J Med 338:1741-1751.
7. Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van BA, Gordon RD, Popat R, Cockey L, Mamelok RD. 2005. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352:2705-2713.
8. Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U, Heimpel H, Arnold R, Mertens TH. 1995. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transpl 15:387-393.
9. Jassal SV, Roscoe JM, Zaltzman JS, Mazzulli T, Krajden M, Gadawski M, Cattran DC, Cardella CJ, Albert SE, Cole EH. 1998. Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 9:1697-1708.
10. Jochimsen F, Westhoff T, Engelmann E, Schafer JH, Offermann G, Zidek W. 2003. Late-onset cytomegalovirus reactivation in critically ill renal transplant patients. Transplantation 76:430-432.
11. Kusne S, Shapiro R, Fung J. 1999. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1:187-203.
12. Lavie A, Ostermann N, Brundiers R, Goody RS, Reinstein J, Konrad M, Schlichting I. 1998. Structural basis for eficient phosphorylation of 3′-azidothymidine monophosphate by Escherichia coli thymidylate kinase. Proc Natl Acad Sci USA 95:14045-14050.
13. McLaughlin K, Sandhu S, Wu C, Muirhead N, Hollomby D, Jevnikar A. 2005. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. Nephrol Dial Transplant 20:176-180.
14. Oliveira G, Xavier P, Murphy B, Neto S, Mendes A, Sayegh MH, Guerra LE. 1998. Cytokine analysis of human renal allograft aspiration biopsy cultures supernatants predicts acute rejection. Nephrol Dial Transplant 13:417-422.
15. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry P, Hill CM, Hoffmann EO, Hunsicker LG, Lindlbad AS, Marcussen N, Mihatsch MJ, Nadasdy T, Nickerson P, Olsen TS, Papadimitriou JC, Randhawa PS, Rayner DC, Roberts I, Rose S, Rush D, Salinas-Madrigal L, Salomon DR, Sund S, Tasinen E, Trpkov K, Yamaguchi Y. 1999. The Banff97 working classification of renal allograft pathology. Kidney Int 55:713-723.
16. Reinke P, Fietze E, Ode-Hakim S, Prosch S, Lippert J, Ewert R, Volk HD. 1994. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 344:1737-1738.
17. Reinke P, Prösch S, Kern F, Volk H-D. 1999. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1:157-164.
18. Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A, Osnes K, Leivestad T, Fauchald P, Rollag H. 2000. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 70:1166-1174.
19. Sagedal S, Hartmann A, Nordal KP, Osnes K, Leivestad T, Foss A, Degre M, Fauchald P, Rollag H. 2004. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66:329-337.
20. Sia IG, Patel R. 2000. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 13:83-121.
21. Singh N. 2001. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 32:742-751.
22. Soderberg-Naucler C, Fish KN, Nelson JA. 1997. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119-126.
23. von Müller L, Hampl W, Hinz J, Meisel H, Reip A, Engelmann E, Heilbronn R, Gärtner B, Krämer O, Einsele H, Hebart H, Ljubicic T, Löffler J, Mertens TH. 2002. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 40:2285-2287.